Search Results

Novo Nordisk today presented the full results from FLOW, its phase 3b kidney outcomes trial investigating the effects of once-weekly injectable semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease (CKD), at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA).

Novo Nordisk launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don’t have to manage their weight alone.

Intern alumni from Moda Health and Novo Nordisk Inc. join forces with the AMCP Foundation for a groundbreaking Health Disparities research internship, appointing Daria Sinclair, a PharmD Candidate at Howard University, College of Pharmacy, as the inaugural intern.

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.